MX9601071A - Composiciones y metodos para incrementar la inmunogenicidad de celulas tumorales. - Google Patents

Composiciones y metodos para incrementar la inmunogenicidad de celulas tumorales.

Info

Publication number
MX9601071A
MX9601071A MX9601071A MX9601071A MX9601071A MX 9601071 A MX9601071 A MX 9601071A MX 9601071 A MX9601071 A MX 9601071A MX 9601071 A MX9601071 A MX 9601071A MX 9601071 A MX9601071 A MX 9601071A
Authority
MX
Mexico
Prior art keywords
tumor cells
transfected
ligand
immunogenicity
compositions
Prior art date
Application number
MX9601071A
Other languages
English (en)
Inventor
Lieping Chen
Karl Erik Hellstrom
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX9601071A publication Critical patent/MX9601071A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion está dirigida hacia un método para inhibir el crecimiento de las células tumorales. Las células tumorales de un paciente son transfectadas para expresar tanto B7 como ligando de CD2 sobre la superficie de las células tumorales transfectadas y esas células son entonces administradas al paciente. La presencia de las moléculas B7 y ligando de CD2 sobre la superficie de la célula tumoral estimula una amplia respuesta inmunogénica tanto contra las células tumorales transfectadas como no transfectadas y da como resultado la muerte inmunologica de células tumorales localizadas y metastáticas. Las células tumorales transfectadas con B7 y ligando de CD2, o las membranas celulares, sirven como amplificadores inmunes para generar una potente respuesta inmunologica contra los antígenos de superficie presentes sobre las células tumorales.
MX9601071A 1995-03-23 1996-03-22 Composiciones y metodos para incrementar la inmunogenicidad de celulas tumorales. MX9601071A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40976895A 1995-03-23 1995-03-23

Publications (1)

Publication Number Publication Date
MX9601071A true MX9601071A (es) 1997-02-28

Family

ID=23621882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9601071A MX9601071A (es) 1995-03-23 1996-03-22 Composiciones y metodos para incrementar la inmunogenicidad de celulas tumorales.

Country Status (4)

Country Link
EP (1) EP0733373A3 (es)
JP (1) JPH0912479A (es)
CA (1) CA2172436A1 (es)
MX (1) MX9601071A (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
WO1999042585A1 (en) * 1998-02-24 1999-08-26 Sisters Of Providence In Oregon Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US6682741B1 (en) 1998-06-10 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services β2 microglobulin fusion proteins and high affinity variants
FR2822846B1 (fr) * 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2107537C (en) * 1992-10-02 2007-01-30 Lieping Chen Inhibition of tumor cell growth by administration of b7-transfected cells

Also Published As

Publication number Publication date
EP0733373A3 (en) 1999-04-28
JPH0912479A (ja) 1997-01-14
CA2172436A1 (en) 1996-09-24
EP0733373A2 (en) 1996-09-25

Similar Documents

Publication Publication Date Title
IL106896A0 (en) Soluble ligands for cd40
CA2107537A1 (en) Inhibition of tumor cell growth by administration of b7-transfected cells
IE802744L (en) Platinum (iv)-diamine complexes
AU588806B2 (en) Drug, and methods of preparing and using it for treatment of tumors
MY121548A (en) Compounds and methods for the treatment of cancer
DE69505391D1 (de) Implantierte vorrichtung mit tumorzellen zur behandlung von krebs
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
AU579461B2 (en) Bi-modal silicone emulsions, silicone emulsification process and emulsions therefrom
DK0912192T3 (da) Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
MX9601071A (es) Composiciones y metodos para incrementar la inmunogenicidad de celulas tumorales.
CA2258104A1 (en) Process for the preparation of alkoxysilanes
WO1998029138A3 (en) Compositions and methods for tumour therapy
EP0951475A4 (en) Vaccine against metastatic colorectal cancer.
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
WO1998003518A3 (en) New bis-platinum complexes with polymethylene derivatives as ligands having antitumor activity
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
BG101125A (en) Low molecular biologically active substance of yeasts and method for its preparation
WO1999052546A3 (en) A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient
AU4042795A (en) Treatment of non-small cell lung carcinoma
MD916G2 (ro) Unguent pentru tratamentul afecţiunilor dentare
WO2001070130A3 (en) Compositions derived from modiolus modiolus and methods for making and using same
ES8606898A1 (es) Un procedimiento para producir un factor regulador de cancerendogeno humano
WO2001092484A3 (en) Adjuvant preparation for the induction of specific immunity
Burgos Jr We Forum, vol vi No. 26-July 28-30, 1982
Burgos Jr We Forum, vol xix No. 12-July 17-23, 1995